Dr. Jacobson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1001 Potrero Ave
Bldg 80 Ward 84
San Francisco, CA 94110Phone+1 415-476-4082Fax+1 415-476-6953- Is this information wrong?
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Infectious Disease, 1984 - 1986
- Kaiser Permanente Northern California (Oakland)Residency, Internal Medicine, 1981 - 1984
- University of California San Francisco School of MedicineClass of 1981
Certifications & Licensure
- CA State Medical License 1982 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM Start of enrollment: 2006 Sep 01
- Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge Start of enrollment: 2006 Oct 01
- Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults Start of enrollment: 2010 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- A Rapid Nucleic Acid Amplification Test-Based, Conditional Release-to-Work Policy for Health Care Personnel With Symptoms Consistent With COVID-19.Mark A Jacobson, Colin Hart, Will Huen, Griselda Suarez Guardado, Allyson Villanueva, Jeffrey Whitman, Paul D Blanc> ;Journal of Occupational and Environmental Medicine. 2023 Feb 1
- 13 citationsIncidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 SARS-CoV2 Vaccine (Moderna) in a Cohort of Hospital Employees.Mark A. Jacobson, Adam Zakaria, Zaw Maung, Colin Hart, Timothy H. McCalmont, Marlys S. Fassett, Erin Amerson> ;Clinical Infectious Diseases. 2021 Jun 4
- 31 citationsAlterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status.Rachel M. Presti, Scott A. Handley, Lindsay Droit, Mahmoud A. Ghannoum, Mark A. Jacobson, Caroline H. Shiboski, Jennifer Webster-Cyriaque, Todd T. Brown, Michael T. Yi...> ;AIDS. 2018 Jun 19
- Join now to see all
Grant Support
- HIV Epitope Specific T Cell Responses And Control Of HIV ReplicationNational Institute Of Allergy And Infectious Diseases2007–2008
- Aberrant T Cell Function And Immunopathogenesis Of CMV Immune Recovery UveitisNational Eye Institute2007–2008
- The Role Of Protein Loop Flexibility In Substrate BindingNational Center For Research Resources2006
- The Role Of Protein Loop Flexibility In Substrate BindingNational Center For Research Resources2005
- CMV Immune Response &Long-Term Outcome Of CMV RetinitisNational Eye Institute2004–2005
- Adjuvant Rhil-12 With A CytomegalovirusNational Center For Research Resources2004–2005
- Aactg 5079: Physiologic TestosteroneNational Center For Research Resources2004–2005
- ACTG 5077: Haart/Hiv CompartmentsNational Center For Research Resources2004
- Aactg A5082: Metformin/ RosiglitazoneNational Center For Research Resources2004
- A5159: HIV Protease Inhibitors And Calcium Channel BlockersNational Center For Research Resources2004
- Adjunct Rhil-12 Enhance Thi Response To Viral Vaccine?National Institute Of Allergy And Infectious Diseases2002–2004
- Salvage Antiretroviral Therapy For HIV+ PatientsNational Center For Research Resources2000–2002
- Quadruple Drug Treatment With 3tc/Zdv PLUS ABC PLUS APV In HIV InfectionNational Center For Research Resources2000–2002
- PI And NRTI In HIV TherapyNational Center For Research Resources2000–2002
- Phase I Trial Of IL-12 In HIV Infected SubjectsNational Center For Research Resources2000–2002
- Interaction Between PI And Lipid Lowering AgentsNational Center For Research Resources2000–2002
- HIV Protease Inhibitors And Methadone Metabolism In HIV+ SubjectsNational Center For Research Resources2000–2002
- Dmp-266 Or Nfv PLUS Combivir And Indinavir In HIVNational Center For Research Resources2000–2002
- Discontinuing Therapy For Disseminated MACNational Center For Research Resources2000–2002
- Amprenavir As PART Of Dual Protease Inhibitor RegimensNational Center For Research Resources2000–2002
- Core--ClinicalNational Institute Of Mental Health1998–2001
- Adult AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1992–2001
- ACTG 387: Paired Combinations Of Nelfinavir, Ritonavir, &SaquinavirNational Center For Research Resources1999–2000
- Safety, Tolerance And Activity On Plasma Viremia Of SCH 52000 In HIVNational Center For Research Resources1998–2000
- Trial To Evaluate Tolerability, Anti CMV Activity/Pharmacokinetics Of 1263w94National Center For Research Resources1997–2000
- Fluconazole, Clarithromycin, Rifabutin/Sulfamethoxazole And DapsoneNational Center For Research Resources1997–1999
- Women'S Health AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
- Pharmacology AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
- Outreach AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
- Outcomes Committee AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
- Neurology AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
- Immunology And Immune Based Therapy AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
- HIV Disease Research AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
- Core--Advanced Technology LaboratoriesNational Institute Of Allergy And Infectious Diseases1996–1999
- Complications Of HIV Disease AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
- Core--ClinicalNational Institute Of Allergy And Infectious Diseases1994–1998
- Oral Ganciclovir After Treatment With IV Ganciclovir For CMV GI DiseaseNational Center For Research Resources1996–1997
- Hpmpc Peripheral CMV Retinitis TrialNational Center For Research Resources1996–1997
- Recombinant Human Interleukin 12 In HIV Infected Subjects--301 To 500 CD4 CellsNational Center For Research Resources1996
- Recombinant Human Interleukin 12 In HIV Infected Subjects--100 To 300 CD4 CellsNational Center For Research Resources1996
- Recombinant Human Interleukin 12 In HIV Infected Subjects (301-500 CD4 Cells)National Center For Research Resources1995
- Recombinant Human Interleukin 12 In HIV Infected Subjects (100-300 CD4 Cells)National Center For Research Resources1995
- AIDS Clinical TrialsNational Institute Of Allergy And Infectious Diseases1994–1995
Hospital Affiliations
- Zuckerberg San Francisco General Hospital and Trauma CenterSan Francisco, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: